Evaluation of Antidiabetic Drug Utilization Using the Atc/DDD and Du 90% Methods at Puskesmas Mrican

Diabetes mellitus is a chronic metabolic disorder that requires long-term pharmacological therapy and continuous monitoring of drug utilization. Evaluation of antidiabetic drug utilization is essential to identify prescribing patterns and support rational drug use in healthcare facilities. This study aimed to evaluate the utilization of antidiabetic drugs among outpatients with type 2 diabetes mellitus at Puskesmas Mrican using the Anatomical Therapeutic Chemical/Defined Daily Dose (ATC/DDD) and Drug Utilization 90% (DU 90%) methods. This study employed a non-experimental observational design with a retrospective descriptive approach using a total sampling technique. The study sample consisted of 330 outpatient prescriptions of patients with type 2 diabetes mellitus during the June–September 2022 period that met the inclusion criteria. Data were analyzed using the ATC/DDD method to calculate DDD/1000 outpatient visits and the DU 90% method to identify the most dominantly utilized drugs. The results showed that the average daily utilization of metformin, glibenclamide, and glimepiride remained within the Defined Daily Dose (DDD) range recommended by the World Health Organization. Glimepiride demonstrated the highest DDD/1000 outpatient visits values, namely 33.33 in June, 32.29 in July, 32.89 in August, and 30.30 in September. DU 90% analysis indicated that glimepiride, metformin, and glibenclamide were included in the DU 90% segment, with glimepiride being the most predominantly utilized antidiabetic drug. This study provides an overview of antidiabetic drug utilization patterns in primary healthcare facilities and may serve as a basis for drug use evaluation to support the quality of pharmaceutical care services.